TY - JOUR AU - Taylor, W. J. AU - Mease, P. J. AU - Adebajo, A. PY - 2010 DA - 2010// TI - Effect of Psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health JO - J Rheumatol VL - 37 UR - https://doi.org/10.3899/jrheum.091315 DO - 10.3899/jrheum.091315 ID - Taylor2010 ER - TY - JOUR AU - Gladman, D. D. AU - Antoni, C. AU - Mease, P. PY - 2005 DA - 2005// TI - Psoriatic arthritis: epidemiology, clinical features, course, and outcome JO - Ann Rheum Dis VL - Suppl 2 ID - Gladman2005 ER - TY - JOUR AU - Mease, P. J. AU - Armstrong, A. W. PY - 2014 DA - 2014// TI - Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of Psoriatic arthritis in patients with psoriasis JO - Drugs. VL - 74 UR - https://doi.org/10.1007/s40265-014-0191-y DO - 10.1007/s40265-014-0191-y ID - Mease2014 ER - TY - JOUR AU - Kang, E. J. AU - Kavanaugh, A. PY - 2015 DA - 2015// TI - Psoriatic arthritis: latest treatments and their place in therapy JO - Ther Adv Chronic Dis. VL - 6 UR - https://doi.org/10.1177/2040622315582354 DO - 10.1177/2040622315582354 ID - Kang2015 ER - TY - JOUR AU - Schett, G. AU - Lories, R. J. AU - D’Agostino, M. A. PY - 2017 DA - 2017// TI - Enthesitis: from pathophysiology to treatment JO - Nat Rev Rheumatol VL - 13 UR - https://doi.org/10.1038/nrrheum.2017.188 DO - 10.1038/nrrheum.2017.188 ID - Schett2017 ER - TY - JOUR AU - Savolainen, E. AU - Kaipiainen-Seppanen, O. AU - Kroger, L. PY - 2003 DA - 2003// TI - Total incidence and distribution of inflammatory joint diseases in a defined population: results from the Kuopio 2000 arthritis survey JO - J Rheumatol VL - 30 ID - Savolainen2003 ER - TY - JOUR AU - Rantalaiho, V. AU - Kautiainen, H. AU - Virta, L. PY - 2016 DA - 2016// TI - FRI0560 the increase in the nationwide incidence of inflammatory rheumatic diseases in finland during this millennium JO - Ann Rheum Dis VL - 75 ID - Rantalaiho2016 ER - TY - JOUR AU - Kavanaugh, A. AU - Helliwell, P. AU - Ritchlin, C. T. PY - 2016 DA - 2016// TI - Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of Psoriasis and Psoriatic arthritis (MAPP) survey JO - Rheumatol Ther. VL - 3 UR - https://doi.org/10.1007/s40744-016-0029-z DO - 10.1007/s40744-016-0029-z ID - Kavanaugh2016 ER - TY - JOUR AU - Lee, S. AU - Mendelsohn, A. AU - Sarnes, E. PY - 2010 DA - 2010// TI - The burden of Psoriatic arthritis: a literature review from a global health systems perspective JO - Pharm Ther VL - 35 ID - Lee2010 ER - TY - JOUR AU - Gossec, L. AU - Smolen, J. S. AU - Gaujoux-Viala, C. PY - 2012 DA - 2012// TI - European league against rheumatism recommendations for the management of Psoriatic arthritis with pharmacological therapies JO - Ann Rheum Dis VL - 71 UR - https://doi.org/10.1136/annrheumdis-2011-200350 DO - 10.1136/annrheumdis-2011-200350 ID - Gossec2012 ER - TY - JOUR AU - Gossec, L. AU - Smolen, J. S. AU - Ramiro, S. PY - 2016 DA - 2016// TI - European league against Rheumatism (EULAR) recommendations for the management of Psoriatic arthritis with pharmacological therapies: 2015 update JO - Ann Rheum Dis VL - 75 UR - https://doi.org/10.1136/annrheumdis-2015-208337 DO - 10.1136/annrheumdis-2015-208337 ID - Gossec2016 ER - TY - JOUR AU - Coates, L. C. AU - Kavanaugh, A. AU - Mease, P. J. PY - 2016 DA - 2016// TI - Group for research and assessment of Psoriasis and Psoriatic arthritis 2015 treatment recommendations for Psoriatic arthritis JO - Arthritis Rheumatol. VL - 68 ID - Coates2016 ER - TY - JOUR AU - Ritchlin, C. T. AU - Kavanaugh, A. AU - Gladman, D. D. PY - 2009 DA - 2009// TI - Treatment recommendations for Psoriatic arthritis JO - Ann Rheum Dis VL - 68 UR - https://doi.org/10.1136/ard.2008.094946 DO - 10.1136/ard.2008.094946 ID - Ritchlin2009 ER - TY - STD TI - Psoriasis (skin and joint): Current Care Guidelines. Working group set up by the Finnish Medical Society Duodecim and the Finnish Dermatological Society.: The Finnish Medical Society Duodecim; 2017. http://www.kaypahoito.fi. UR - http://www.kaypahoito.fi ID - ref14 ER - TY - JOUR AU - Boyd, T. AU - Kavanaugh, A. PY - 2015 DA - 2015// TI - Interleukin-17 inhibition in Psoriatic arthritis JO - Clin Exp Rheumatol VL - 33 ID - Boyd2015 ER - TY - STD TI - EMA. Cosentyx: EPAR Product Information. 2016 (Cosentyx-EMEA/H/C/003729-T/0036). ID - ref16 ER - TY - JOUR AU - McInnes, I. B. AU - Mease, P. J. AU - Kirkham, B. PY - 2015 DA - 2015// TI - Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with Psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial JO - Lancet VL - 386 UR - https://doi.org/10.1016/S0140-6736(15)61134-5 DO - 10.1016/S0140-6736(15)61134-5 ID - McInnes2015 ER - TY - JOUR AU - Kavanaugh, A. AU - Mease, P. J. AU - Reimold, A. M. PY - 2016 DA - 2016// TI - Secukinumab for long-term treatment of Psoriatic arthritis: 2-year follow-up from a phase 3, randomized, double-blind, placebo-controlled study JO - Arthritis Care Res. VL - 69 UR - https://doi.org/10.1002/acr.23111 DO - 10.1002/acr.23111 ID - Kavanaugh2016 ER - TY - STD TI - Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab provides sustained improvements in the signs and symptoms of active Psoriatic arthritis through 3 years: efficacy and safety results from a phase 3 trial [abstract]. Arthritis Rheumatol. 2016;68(10). ID - ref19 ER - TY - JOUR AU - Mease, P. J. AU - McInnes, I. B. AU - Kirkham, B. PY - 2015 DA - 2015// TI - Secukinumab inhibition of interleukin-17A in patients with Psoriatic arthritis JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1412679 DO - 10.1056/NEJMoa1412679 ID - Mease2015 ER - TY - JOUR AU - Kavanaugh, A. AU - McInnes, I. B. AU - Mease, P. J. PY - 2016 DA - 2016// TI - Efficacy of subcutaneous Secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study JO - J Rheumatol VL - 43 UR - https://doi.org/10.3899/jrheum.160275 DO - 10.3899/jrheum.160275 ID - Kavanaugh2016 ER - TY - JOUR AU - Mease, P. AU - Kavanaugh, A. AU - Reimold, A. PY - 2017 DA - 2017// TI - Secukinumab provides sustained improvements in the signs and symptoms of active Psoriatic arthritis: 3-year efficacy and safety results from phase 3 FUTURE 1 trial JO - Ann Rheum Dis VL - 76 ID - Mease2017 ER - TY - STD TI - Gottlieb A B DEM, Pellet P, Kajekar R, Pricop L, editor. Secukinumab provides sustained improvement in signs and symptoms of patients with active Psoriatic arthritis up to 3 years: Data from FUTURE 1 and FUTURE 2 studies. EADV. 2017. https://eadvgeneva2017.org/e-congress/online-resources/. Accessed 14 Mar 2018. UR - https://eadvgeneva2017.org/e-congress/online-resources/ ID - ref23 ER - TY - JOUR AU - Wu, D. AU - Yue, J. AU - Tam, L. S. PY - 2018 DA - 2018// TI - Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral Psoriatic arthritis: a network meta-analysis JO - Rheumatology (Oxford) VL - 57 UR - https://doi.org/10.1093/rheumatology/kex452 DO - 10.1093/rheumatology/kex452 ID - Wu2018 ER - TY - JOUR AU - Nash, P. AU - McInnes, I. AU - Mease, P. PY - 2016 DA - 2016// TI - Secukinumab for the treatment of Psoriatic Arthritis: comparative effectiveness versus adalimumab using a matching-adjusted indirect comparison JO - Arthritis Rheumatol. VL - 68 ID - Nash2016 ER - TY - STD TI - Efficacy of Secukinumab compared to adalimumab in patients with Psoriatic arthritis (EXCEED 1) [Internet]. 2017. https://clinicaltrials.gov/ct2/show/NCT02745080. Accessed 12 Dec 2017. UR - https://clinicaltrials.gov/ct2/show/NCT02745080 ID - ref26 ER - TY - JOUR AU - Goeree, R. AU - Chiva-Razavi, S. AU - Gunda, P. PY - 2018 DA - 2018// TI - Cost-effectiveness analysis of Secukinumab for the treatment of active Psoriatic arthritis: a Canadian perspective JO - J Med Econ VL - 21 UR - https://doi.org/10.1080/13696998.2017.1384737 DO - 10.1080/13696998.2017.1384737 ID - Goeree2018 ER - TY - JOUR AU - Rodgers, M. AU - Epstein, D. AU - Bojke, L. PY - 2011 DA - 2011// TI - Etanercept, infliximab and adalimumab for the treatment of Psoriatic arthritis: a systematic review and economic evaluation JO - Health Technol Assess VL - 15 UR - https://doi.org/10.3310/hta15100 DO - 10.3310/hta15100 ID - Rodgers2011 ER - TY - JOUR AU - Woolacott, N. AU - Bravo Vergel, Y. AU - Hawkins, N. PY - 2006 DA - 2006// TI - Etanercept and infliximab for the treatment of Psoriatic arthritis: a systematic review and economic evaluation JO - Health Technol Assess VL - 10 UR - https://doi.org/10.3310/hta10310 DO - 10.3310/hta10310 ID - Woolacott2006 ER - TY - JOUR AU - Bravo Vergel, Y. AU - Hawkins, N. S. AU - Claxton, K. PY - 2007 DA - 2007// TI - The cost-effectiveness of etanercept and infliximab for the treatment of patients with Psoriatic arthritis JO - Rheumatology (Oxford) VL - 46 UR - https://doi.org/10.1093/rheumatology/kem221 DO - 10.1093/rheumatology/kem221 ID - Bravo Vergel2007 ER - TY - JOUR AU - Cawson, M. R. AU - Mitchell, S. A. AU - Knight, C. PY - 2014 DA - 2014// TI - Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active Psoriatic arthritis JO - BMC Musculoskelet Disord. VL - 15 UR - https://doi.org/10.1186/1471-2474-15-26 DO - 10.1186/1471-2474-15-26 ID - Cawson2014 ER - TY - JOUR AU - Bojke, L. AU - Epstein, D. AU - Craig, D. PY - 2011 DA - 2011// TI - Modelling the cost-effectiveness of biologic treatments for Psoriatic arthritis JO - Rheumatology (Oxford) VL - Suppl 4 ID - Bojke2011 ER - TY - JOUR AU - Cummins, E. AU - Asseburg, C. AU - Punekar, Y. S. PY - 2011 DA - 2011// TI - Cost-effectiveness of infliximab for the treatment of active and progressive Psoriatic arthritis JO - Value Health. VL - 14 UR - https://doi.org/10.1016/j.jval.2010.10.016 DO - 10.1016/j.jval.2010.10.016 ID - Cummins2011 ER - TY - JOUR AU - Cummins, E. AU - Asseburg, C. AU - Prasad, M. PY - 2012 DA - 2012// TI - Cost effectiveness of golimumab for the treatment of active Psoriatic arthritis JO - Eur J Health Econ. VL - 13 UR - https://doi.org/10.1007/s10198-011-0335-x DO - 10.1007/s10198-011-0335-x ID - Cummins2012 ER - TY - STD TI - NICE Multiple Technology Appraisal—Certolizumab pegol and Secukinumab for treating active Psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs [Internet]. 2016. https://www.nice.org.uk/guidance/ta445/documents/html-content-3. Accessed 31 Aug 2017. UR - https://www.nice.org.uk/guidance/ta445/documents/html-content-3 ID - ref35 ER - TY - JOUR AU - McInnes, I. AU - Nash, P. AU - Ritchlin, C. PY - 2016 DA - 2016// TI - Secukinumab for the treatment of Psoriatic arthritis: comparative effectiveness results versus licensed biologics and Apremilast from a network meta-analysis JO - Ann Rheum Dis VL - 75 UR - https://doi.org/10.1136/annrheumdis-2014-206418 DO - 10.1136/annrheumdis-2014-206418 ID - McInnes2016 ER - TY - JOUR AU - Reddy, S. M. AU - Crean, S. AU - Martin, A. L. PY - 2016 DA - 2016// TI - Real-world effectiveness of anti-TNF switching in Psoriatic arthritis: a systematic review of the literature JO - Clin Rheumatol VL - 35 UR - https://doi.org/10.1007/s10067-016-3425-4 DO - 10.1007/s10067-016-3425-4 ID - Reddy2016 ER - TY - JOUR AU - Gladman, D. D. AU - Sampalis, J. S. AU - Illouz, O. PY - 2010 DA - 2010// TI - Responses to adalimumab in patients with active Psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study JO - J Rheumatol VL - 37 UR - https://doi.org/10.3899/jrheum.100069 DO - 10.3899/jrheum.100069 ID - Gladman2010 ER - TY - JOUR AU - Conaghan, P. G. AU - Alten, R. AU - Strand, V. PY - 2016 DA - 2016// TI - The relationship between physical functioning and work for people with Psoriatic arthritis: results from a large real-world study in 16 countries JO - Arthritis Rheum VL - 68 ID - Conaghan2016 ER - TY - JOUR AU - Dolan, P. PY - 1997 DA - 1997// TI - Modeling valuations for EuroQol health states JO - Med Care VL - 35 UR - https://doi.org/10.1097/00005650-199711000-00002 DO - 10.1097/00005650-199711000-00002 ID - Dolan1997 ER - TY - JOUR AU - Ogdie, A. AU - Haynes, K. AU - Troxel, A. B. PY - 2014 DA - 2014// TI - Risk of mortality in patients with Psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study JO - Ann Rheum Dis VL - 73 UR - https://doi.org/10.1136/annrheumdis-2012-202424 DO - 10.1136/annrheumdis-2012-202424 ID - Ogdie2014 ER - TY - BOOK AU - Briggs, A. AU - Claxton, K. AU - Sculpher, M. PY - 2006 DA - 2006// TI - Analysing and presenting simulation output from probabilistic models: decision modelling for health economic evaluation PB - Oxford University Press CY - Oxford ID - Briggs2006 ER - TY - JOUR AU - Stoner, K. L. AU - Harder, H. AU - Fallowfield, L. J. PY - 2015 DA - 2015// TI - Intravenous versus subcutaneous drug administration. which do patients prefer? A systematic review JO - Patient. VL - 8 UR - https://doi.org/10.1007/s40271-014-0075-y DO - 10.1007/s40271-014-0075-y ID - Stoner2015 ER - TY - JOUR AU - Tsiantou, V. AU - Athanasakis, K. AU - Theodoropoulou, F. PY - 2015 DA - 2015// TI - Patients’ and health professionals’ preferences regarding intravenous vs subcutaneous drug administration: a literature review JO - Value Health. VL - 18 UR - https://doi.org/10.1016/j.jval.2015.09.2852 DO - 10.1016/j.jval.2015.09.2852 ID - Tsiantou2015 ER - TY - JOUR AU - McInnes, I. AU - Nash, P. AU - Mease, P. PY - 2016 DA - 2016// TI - Secukinumab for the treatment of Psoriatic arthritis: comparative effectiveness results versus adalimumab up to 48 weeks using a matching-adjusted indirect comparison JO - Clin Exp Rheumatol VL - 34 ID - McInnes2016 ER - TY - STD TI - Nash P, McInnes I, Mease P, et al. Secukinumab for Psoriatic arthritis: Comparative effectiveness results versus etanercept up to 24 weeks using a matching-adjusted indirect comparison. In: 8th APLAR Congress, 2016. APL16-0827. ID - ref46 ER - TY - STD TI - Strand V, Mease P, McInnes I, et al. Secukinumab for the treatment of Psoriatic Arthritis: comparative effectiveness versus infliximab using a matching-adjusted indirect comparison. Arthritis Rheumatol. 2016;68(suppl 10). ID - ref47 ER - TY - JOUR AU - Soini, E. J. AU - Leussu, M. AU - Hallinen, T. PY - 2013 DA - 2013// TI - Administration costs of intravenous biologic drugs for rheumatoid arthritis JO - Springerplus. VL - 2 UR - https://doi.org/10.1186/2193-1801-2-531 DO - 10.1186/2193-1801-2-531 ID - Soini2013 ER - TY - JOUR AU - Kobelt, G. AU - Jonsson, L. AU - Young, A. PY - 2003 DA - 2003// TI - The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study JO - Rheumatology (Oxford) VL - 42 UR - https://doi.org/10.1093/rheumatology/keg107 DO - 10.1093/rheumatology/keg107 ID - Kobelt2003 ER - TY - STD TI - (DoH) DoH. Reference costs 2007–08. London:DoH: 2009. ID - ref50 ER - TY - JOUR AU - Hartman, M. AU - Prins, M. AU - Swinkels, O. Q. PY - 2002 DA - 2002// TI - Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment JO - Br J Dermatol VL - 147 UR - https://doi.org/10.1046/j.1365-2133.2002.04920.x DO - 10.1046/j.1365-2133.2002.04920.x ID - Hartman2002 ER -